Avidity Biosciences inks drug discovery deal worth up to $2.3B with industry heavyweight

“This strategic collaboration solidifies our commitment in cardiology as we continue to advance our own research and development programs in cardiac indications,” Sarah Boyce, president and chief executive officer at Avidity, said in a statement. “We look forward to broadening the utility of the AOC platform to address debilitating diseases previously unreachable with existing RNA therapies.”

“This collaboration with Avidity represents an important part of our continued investment in innovative therapeutic approaches that have the potential to provide transformative outcomes to patients living with serious cardiovascular conditions,” added Francisco Ramírez-Valle, MD, PhD, senior vice president and head of the Immunology & Cardiovascular Thematic Research Center at Bristol Myers Squibb. “Aligned with our focus on causal human biology and efforts to successfully match therapeutic modalities to disease mechanism, our R&D organization will continue to leverage technologies like Avidity’s AOC platform to identify meaningful targets and develop new medicines for patients in need.”